Insider · CIK 0001670579
Rachel E. Haurwitz
Files at CRBU (Caribou Biosciences, Inc.). First filing Mar 17, 2025, latest Mar 17, 2025.
Rachel E. Haurwitz files SEC Form 4 as CEO, president and director at CRBU (Caribou Biosciences, Inc.). Since Mar 17, 2025, Rachel E. Haurwitz has reported 1 open-market buy worth $20k and 0 open-market sells worth $0, the latest filed on Mar 17, 2025.
A track record needs three past buys with six months of prices behind them; Rachel E. Haurwitz has 0, so none is measured yet.
The newest scored trade: bought $20k of CRBU on Mar 14, 2025, filed Mar 17, 2025, scored 20 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CRBU: Caribou Biosciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 20Weak | CRBUbuy Caribou Biosciences, Inc. | $20k 20,000 shares | +1% | - |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 20, 2026 | CRBU Caribou Biosciences, Inc. | AGrant or award Common Stock | +151,700 | $0.00 | $0 | 447,150 | Feb 20, 2026 |
| Feb 20, 2026 | CRBU Caribou Biosciences, Inc. | AGrant or award Option to purchase Common Stockderivative | +682,500 | $0.00 | $0 | 682,500 | Feb 20, 2026 |
| Mar 14, 2025 | CRBU Caribou Biosciences, Inc. | POpen-market purchase Common Stockindirect: By Trust | +20,000 | $1.02 | $20k | 3,369,395 | Mar 17, 2025 |
| Feb 20, 2025 | CRBU Caribou Biosciences, Inc. | AGrant or award Common Stock | +136,750 | $0.00 | $0 | 295,450 | Feb 21, 2025 |
| Feb 20, 2025 | CRBU Caribou Biosciences, Inc. | AGrant or award Option to purchase Common Stockderivative | +618,250 | $0.00 | $0 | 618,250 | Feb 21, 2025 |
Questions about Rachel E. Haurwitz
Answered from the filings on this page, as of the latest one.
Is Rachel E. Haurwitz buying or selling?
Not in the last 12 months. Rachel E. Haurwitz's latest open-market trade on SEC Form 4 was bought $20k of CRBU on Mar 14, 2025.
How did Rachel E. Haurwitz's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Rachel E. Haurwitz has 0.
Where does Rachel E. Haurwitz file Form 4?
Rachel E. Haurwitz has filed Form 4 at CRBU (Caribou Biosciences, Inc.) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.